Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Rivero Juárez, Antonio ^a   Camacho, Angela ^a   Merchante, Nicolás ^b   Pérez Camacho, Inés ^c   Macias, Juan ^b   Ortiz Garcia, Carmen ^a   Cifuentes, Celia ^b   Torre Cisneros, Julián ^a   Peña, José ^a   Pineda, Juan A ^b   Rivero, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL DE PONIENTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL LIVER STIFFNESS; ADULT; ARTICLE; DIGESTIVE TRACT PARAMETERS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER DAMAGE OF UNCERTAIN ORIGIN; LIVER DISEASE; LIVER INJURY; LIVER STIFFNESS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATHOGENESIS; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANALYSIS OF VARIANCE; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER DISEASES; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84880411241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068953     Document Type: Article

References (30)

1. Hernando V, Sobrino-Vegas P, Burriel MC, Berenguer J, Navarro G, et al. (2012) Differences in the causes of death of HIV-positive subjects in a cohort study by data sources and coding algorithms. AIDS. 26: 1829-1834.
2. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, et al. (2012) Mortality in HCV-infected Patients with a Diagnosis of AIDS in the Era of Combination Anti-retroviral Therapy. Clin Infect Dis. 55: 137-144.
3. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P, (2010) Viral hepatitis and HIV co-infection. Antiviral Res. 85: 303-15.
4. Maida I, Núñez M, Rios MJ, Martín-Carbonero L, Sotgiu G, et al. (2006) Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 42: 177-82.
5. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, et al. (2008) Antiretroviral associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther. 13: 103-107.
6. Schiano TD, Kotler DP, Ferran E, Fiel MI, (2007) Hepatoportal sclerosis is a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol. 102: 2536-2540.
7. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, et al. (2007) Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 21: 187-192.
8. Merchante N, Perez-Camacho I, Mira JA, Rivero A, Macías J, et al. (2010) Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther. 15: 753-763.
9. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, et al. (2011) High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 16: 405-11.
10. Neuman M, Schneider M, Nanau RM, Parry C, (2012) HIV-Antiretroviral therapy induced liver, gastrointestinal and pancreatic injury. Int J Hepatol. 2012: 760706.
11. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AntiviralSociety-USA panel. JAMA. 308: 387-402.
12. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, et al. (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 45: 969-74.
13. Castera L, Forns X, Alberti A, (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.
14. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, et al. (2003) Diagnosing Insulin Resistance by Simple Quantitative Methods in Subjects with Normal Glucose Metabolism. Diabetes Care 26: 3320-3325.
15. Scheuer PJ, (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13: 372-374.
16. Wanless IR, (1990) Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11: 787-797.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR, (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-74.
18. Harrell FE Jr, Lee KL, Mark DB, (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 15: 361-87.
19. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-31.
20. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, et al. (2005) Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41: 64-71.
21. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, et al. (2005) The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 143: 722-8.
22. Whalley S, Puvanachandra P, Desai A, Kennedy H, (2007) Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 7: 119-24.
23. Kim AY, Chung RT, (2009) Coinfection with HIV-1 and HCV: a one-two punch. Gastroenterol 137: 795-814.
24. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, et al. (2009) Nonalcoholic Fatty Liver Disease (NAFLD) among HIV-Infected Persons. J Acquir Immune Defic Syndr 50: 464-473.
25. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, et al. (2008) Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. Clin Infec Dis 47: 250-7.
26. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, et al. (2009) Liver Damage Underlying Unexplained Transaminase Elevation in Human Immunodeficiency Virus-1 Monoinfected Patients on Antiretroviral Therapy. Hepatology 47: 436-442.
27. Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, et al. (2011) Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. Arch Med Res 42: 690-7.
28. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Gastroenterol 142: 1592-609.
29. Vernon G, Baranova A, Younossi ZM, (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.
30. Li Vecchi V, Soresi M, Giannitrapani L, Di Carlo P, Mazzola G, et al. (2012) Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis 16: e397-402.